OTC · Biotechnology

Claritas Pharmaceuticals, Inc. (CLAZF) Stock

$0.00 OTC: CLAZF Healthcare

Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled.

Valuation

MetricValue
Price$0.00
Market Cap$3659
P/E Ratio0.00
P/B Ratio0.00
P/S Ratio0.00
EPS (TTM)$0.16
52-Week High$0.00
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE200.00%
ROA40.00%
ROCE-98.76%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.50
Current Ratio0.14

Annual Financials (USD)

Metric20162017201820192020
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-14.0M$-11.0M$-9.0M$-3.0M
Net Profit$-12.0M$-32.0M$7.0M$-21.0M$4.0M
EPS$-7.80$-5.20$0.64$-1.00$0.16
Op Margin—————

Balance Sheet (USD)

Metric20162017201820192020
Total Assets$5.0M$65.0M$60.0M$25.0M$10.0M
Total Liabilities$2.0M$77.0M$50.0M$29.0M$9.0M
Cash$1.0M$4.0M$0$0$0
Borrowings$0$3.0M$0$1.0M$1.0M

Cash Flow (USD)

Metric20162017201820192020
Operating Cash Flow$-2.0M$-6.0M$-5.0M$-6.0M$0
Investing Cash Flow$0$-10.0M$0$0$0
Financing Cash Flow$0$0$-2.0M$0$0
Net Cash Flow$0$3.0M$-3.0M$0$0
Free Cash Flow$-2.0M$-6.0M$-5.0M$-6.0M$0

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.05
FCF Yield-8444.93%
Quick Ratio0.14
Interest Coverage-14.56
Return 1Y0.00%
Return 3Y-50.00%
Return 5Y-99.97%

Ownership

Insiders Held0.26%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
GFG Capital, LLC4,3332025-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Claritas Pharmaceuticals, Inc.

Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. Established in 2014, the company was previously known as Kalytera Therapeutics, Inc. before rebranding to Claritas Pharmaceuticals, Inc. in April 2021. Its corporate headquarters are located in San Rafael, California.

Claritas Pharmaceuticals, Inc. (CLAZF) stock trades at $0.00 with a market capitalization of $3659. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.

On profitability, Claritas Pharmaceuticals, Inc. generates a return on equity (ROE) of 200.00% — well above the market average, a sign of a high-quality business, return on capital employed of -98.76%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: claritaspharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides